法国不同RSVpreF孕产妇疫苗策略对婴儿RSV感染影响的健康经济学评估
本研究用三态马尔可夫模型模拟法国627499名新生儿在四种RSVpreF孕产妇疫苗接种策略下的RSV住院负担。与不接种相比,推荐策略(9月至1月接种)避免7620例住院,每避免一例住院需接种21人;延长策略(5月至1月)额外避免4111例住院,总费用增加6.3%。
要点
- 推荐策略避免19.7%的RSV相关住院,其中90.4%为<3月龄婴儿。
- 延长策略较推荐策略额外避免4111例住院,每额外避免一例住院成本1929欧元。
- 全年接种策略总费用156.2百万欧元,额外避免1306例住院。
核心结论
- 推荐策略可避免7620例RSV相关住院,每避免一例住院需接种21人。
- 延长策略较推荐策略额外避免4111例住院,总费用增加6.3%。
- 全年接种策略总费用156.2百万欧元,额外避免1306例住院。
研究设计与样本
- 三态马尔可夫模型(易感、RSV相关住院、死亡),评估替代接种策略避免的住院数。
- 模型人群为一年内627499名新生儿,分为接种和未接种母亲所生婴儿两个队列。
- 模拟四种策略:不接种、9月至1月接种(推荐)、5月至1月接种(延长)、全年接种。
- 从医疗保健视角以每避免一例住院成本和需接种人数(NNV)呈现结果。
主要发现
- 推荐策略避免7620例(-19.7%)住院,其中90.4%为<3月龄婴儿(99.5%为<6月龄)。
- 延长策略较推荐策略额外避免4111例(-13.3%)住院,其中42.0%为<3月龄婴儿(95.0%为<6月龄)。
临床怎么用
- 推荐策略(9月至1月接种)可有效减少<3月龄婴儿RSV住院负担。
- 延长策略(5月至1月)可进一步减少住院,总费用增加有限。
- 决策时可参考NNV(21)和每避免一例住院成本(844欧元)评估推荐策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Most of the clinical and economic burden of the respiratory syncytial virus (RSV) in pediatric populations is concentrated among infants aged <1 year. Since 2024, RSVpreF vaccine is available in France for the vaccination of pregnant women between 32 and 36 weeks of gestational age, from September to January. This study aimed to model the impact of alternative RSVpreF national vaccination strategies on RSV hospital burden. METHODS: A three-state Markov model - Susceptible to be infected, RSV-related hospitalization, and Death - was developed to assess the number of hospitalizations avoided by alternative vaccination strategies. The model population of 627,499 unique births in one year was split in two cohorts of infants born to vaccinated and unvaccinated women. Four strategies were modeled: no vaccination, vaccination between September and January (recommended), between May and January (extended), and year-round. Results were presented at a population level using a healthcare perspective, as cost per hospitalization avoided, and number needed to vaccinate (NNV). RESULTS: In the absence of vaccination, 38,625 RSV-related hospitalization among infants under 1 year of age were estimated annually, costing €120.0 million. Compared to no vaccination, the recommended strategy prevented 7,620 (-19.7%) RSV-related hospitalizations, 90.4% of them involved infants aged <3 months (99.5% aged <6 months). The related total cost was €126.4 million, corresponding to cost of €844 per hospitalization avoided, and an NNV of 21 vaccinations to avoid one hospitalization. Compared to the recommended strategy, the extended strategy avoided an additional 4,111 (-13.3%) hospitalizations, 42.0% of them involving infants aged <3 months (95.0% aged <6 months). The total cost of this strategy was €134.4 million (+6.3%), corresponding to a cost of €1,929 per additional hospitalization avoided. Total cost of the year-round strategy was €156.2 million, for 1,306 additional hospitalizations avoided. CONCLUSIONS: This is the first cost-effectiveness model to describe the public health impact of alternative vaccination strategies for RSV prevention in France. The number of hospitalizations avoided ranged from 7,600 stays in the recommended strategy, to more than 13,000 in the year-round strategy, corresponding to hospital savings between €24.7 million and €41.5 million. Alternative scenarios were shown to extend prevention to older age groups. Broader vaccination strategies, notably the extended strategy, had a positive impact on RSV hospital burden, with a limited impact on total costs.
引用
- Fahfouhi Y, Fiévez S, Cohen R, et al. A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT. Vaccine. 2026. PMID: 42628195. doi:10.1016/j.vaccine.2026.129036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。